Advertisement

Current Allergy and Asthma Reports

, Volume 13, Issue 2, pp 203–208 | Cite as

Role of Leukotriene Antagonists and Antihistamines in the Treatment of Allergic Rhinitis

  • Bengü Çobanoğlu
  • Elina Toskala
  • Ahmet Ural
  • Cemal Cingi
RHINITIS (JN BARANIUK AND JJ OPPENHEIMER, SECTION EDITORS)

Abstract

Allergic rhinitis is the most common atopic disorder seen in ENT clinics. It is diagnosed by history, physical exam and objective testing. Patient education, environmental control measures, pharmacotherapy, and allergen-specific immunotherapy are the cornerstones of allergic rhinitis treatment and can significantly reduce the burden of disease. Current treatment guidelines include antihistamines, intranasal corticosteroids, oral and intranasal decongestants, intranasal anticholinergics, intranasal cromolyn, and leukotriene receptor antagonists. In the mechanism of allergic rhinitis, histamine is responsible for major allergic rhinitis symptoms such as rhinorrhea, nasal itching and sneezing. Its effect on nasal congestion is less evident. In contrast, leukotrienes result in increase in nasal airway resistance and vascular permeability. Antihistamines and leukotriene receptor antagonists are commonly used in the treatment of allergic rhinitis. The published literature about combined antihistamines and leukotriene antagonists in mono- or combination therapy is reviewed and presented.

Keywords

Allergic rhinitis Early phase Late phase Antihistamines Montelukast Leukotrienes Leukotriene antagonists Treatment Histamine 

Notes

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

  1. 1.
    Valk PJ, Simons M. Effects of loratadine/montelukast on vigilance and alertness task performance in a simulated cabin environment. Adv Ther. 2009;26(1):89–98.PubMedCrossRefGoogle Scholar
  2. 2.
    Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8–160.PubMedCrossRefGoogle Scholar
  3. 3.
    Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wei LX, Weinstein SF, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000;105(5):917–22.PubMedCrossRefGoogle Scholar
  4. 4.
    Cingi C, Kayabasoglu G, Nacar A. Update on the medical treatment of allergic rhinitis. Inflamm Allergy Drug Targets. 2009;8(2):96–103.PubMedCrossRefGoogle Scholar
  5. 5.
    Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1–12.PubMedGoogle Scholar
  6. 6.
    Van Hoecke H, Vandenbulcke L, Van Cauwenberge P. Histamine and leukotriene receptor antagonism in the treatment of allergic rhinitis: an update. Drugs. 2007;67(18):2717–26.PubMedCrossRefGoogle Scholar
  7. 7.
    Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy. 2009;64 Suppl 91:1–59.PubMedGoogle Scholar
  8. 8.
    Lagos JA, Marshall GD. Montelukast in the management of allergic rhinitis. Ther Clin Risk Manag. 2007;3(2):327–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Al Suleimani YM, Walker MJ. Allergic rhinitis and its pharmacology. Pharmacol Ther. 2007;114(3):233–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811.PubMedCrossRefGoogle Scholar
  11. 11.
    Lambrecht BN. Allergen uptake and presentation by dendritic cells. Curr Opin Allergy Clin Immunol. 2001;1(1):51–9.PubMedGoogle Scholar
  12. 12.
    Takhar P, Corrigan CJ, Smurthwaite L, O’Connor BJ, Durham SR, Lee TH, et al. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol. 2007;119(1):213–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Grønborg H, Bisgaard H, Rømeling F, Mygind N. Early and late nasal symptom response to allergen challenge. The effect of pretreatment with a glucocorticosteroid spray. Allergy. 1993;48(2):87–93.PubMedCrossRefGoogle Scholar
  14. 14.
    Min YG. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res. 2010;2(2):65–76.PubMedCrossRefGoogle Scholar
  15. 15.
    Mandhane SN, Shah JH, Thennati R. Allergic rhinitis: an update on disease, present treatments and future prospects. Int Immunopharmacol. 2011;11(11):1646–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Smith LJ. Pharmacology and safety of the leukotriene antagonists. Clin Rev Allergy Immunol. 1999;17(1–2):195–212.PubMedCrossRefGoogle Scholar
  17. 17.
    Venarske D, de Shazo RD. Molecular mechanisms of allergic disease. South Med J. 2003;96(11):1049–54.PubMedCrossRefGoogle Scholar
  18. 18.
    Iademarco MF, Barks JL, Dean DC. Regulation of vascular cell adhesion molecule-1 expression by IL-4 and TNF-alpha in cultured endothelial cells. J Clin Investig. 1995;95(1):264–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Taylor-Clark T, Foreman J. Histamine-mediated mechanisms in the human nasal airway. Curr Opin Pharmacol. 2005;5(3):214–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Doyle WJ, Boehm S, Skoner DP. Physiologic responses to intranasal dose-response challenges with histamine, methacholine, bradykinin, and prostaglandin in adult volunteers with and without nasal allergy. J Allergy Clin Immunol. 1990;86(6 Pt 1):924–35.PubMedCrossRefGoogle Scholar
  21. 21.
    Baroody FM, Naclerio RM. Antiallergic effects of H1-receptor antagonists. Allergy. 2000;55(64):17–27.PubMedCrossRefGoogle Scholar
  22. 22.
    Nakaya M, Takeuchi N, Kondo K. Immunohistochemical localization of histamine receptor subtypes in human inferior turbinates. Ann Otol Rhinol Laryngol. 2004;113(7):552–7.PubMedGoogle Scholar
  23. 23.
    Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol. 2003;112(1):15–22.PubMedCrossRefGoogle Scholar
  24. 24.
    Camelo-Nunes IC. Newantihistamines: a critical view. J Pediatr (Rio J). 2006;82(5):S173–80.CrossRefGoogle Scholar
  25. 25.
    Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76.PubMedCrossRefGoogle Scholar
  26. 26.
    Cingi C, Gunhan K, Gage-White L, Unlu H. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope. 2010;120(9):1718–23.PubMedCrossRefGoogle Scholar
  27. 27.
    Lee C, Corren J. Review of azelastine nasal spray in the treatment of allergic and non-allergic rhinitis. Expert Opin Pharmacother. 2007;8(5):701–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Canonica GW, Ciprandi G, Petzold U, Kolb C, Ellers-Lenz B, Hermann R. Topicalazelastine in perennial allergic conjunctivitis. Curr Med Res Opin. 2003;19(4):321–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Murphy RC, Hammarström S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A. 1979;76(9):4275–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Peters-Golden M, Gleason MM, Togias A. Cysteinylleukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy. 2006;36(6):689–703.PubMedCrossRefGoogle Scholar
  31. 31.
    Haberal I, Corey JP. The role of leukotrienes in nasal allergy. Otolaryngol Head Neck Surg. 2003;129(3):274–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Peters-Golden M, Henderson Jr WR. The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol. 2005;94(6):609–18.PubMedCrossRefGoogle Scholar
  33. 33.
    Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest. 2005;127(4):1312–26.PubMedCrossRefGoogle Scholar
  34. 34.
    Elnabtity MH, Singh RF, Ansong MA, Craig TJ. Leukotriene modifiers in the management of asthma. J Am Osteopath Assoc. 1999;99(7):S1–6.PubMedGoogle Scholar
  35. 35.
    Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007;67(6):887–901.PubMedCrossRefGoogle Scholar
  36. 36.
    Grainger J, Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and meta-analysis. Clin Otolaryngol. 2006;31(5):360–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Samaria JK. Anti leukotriene drugs: are they really useful? J Indian Acad Clin Med. 2000;5(1):41–4.Google Scholar
  38. 38.
    Kurowski M, Kuna P, Górski P. Montelukastpluscetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy. 2004;59(3):280–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Ciebiada M, Ciebiada MG, Kmiecik T, DuBuske LM, Gorski P. Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine. J Investig Allergol Clin Immunol. 2008;18(5):343–9.PubMedGoogle Scholar
  40. 40.
    Watanasomsiri A, Poachanukoon O, Vichyanond P. Efficacy of montelukast and loratadine as treatment for allergic rhinitis in children. Asian Pac J Allergy Immunol. 2008;26(2–3):89–95.PubMedGoogle Scholar
  41. 41.
    Day JH, Briscoe MP, Ratz JD, Ellis AK, Yao R, Danzig M. Onset of action of loratadine/montelukast in seasonal allergic rhinitis subjects exposed to ragweed pollen in the Environmental Exposure Unit. Allergy Asthma Proc. 2009;30(3):270–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Pullerits T, Praks L, Ristioja V, Lötvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(6):949–55.PubMedCrossRefGoogle Scholar
  43. 43.
    Di Lorenzo G, Pacor ML, Pellitteri ME, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasonepluscetirizine, fluticasoneplus montelukast and cetirizineplus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004;34(2):259–67.PubMedCrossRefGoogle Scholar
  44. 44.
    Rodrigo GJ, Yañez A. The role of anti leukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol. 2006;96(6):779–86.PubMedCrossRefGoogle Scholar
  45. 45.
    Lee DK, Jackson CM, Soutar PC, Fardon TC, Lipworth BJ. Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis. Br J Clin Pharmacol. 2004;57(6):714–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Hay J, Jhaveri M, Tangirala M, Kaliner M. Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment. Allergy Asthma Proc. 2009;30(6):634–42.PubMedCrossRefGoogle Scholar
  47. 47.
    Scadding GW, Scadding GK. Recent advances in antileukotriene therapy. Curr Opin Allergy Clin Immunol. 2010;10(4):370–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Bengü Çobanoğlu
    • 1
  • Elina Toskala
    • 2
  • Ahmet Ural
    • 3
  • Cemal Cingi
    • 4
  1. 1.Department of Otolaryngology-Head Neck SurgeryTrabzon Research and Training HospitalTrabzonTurkey
  2. 2.Department of Otolaryngology-Head and Neck SurgeryTemple University, School of MedicinePhiladelphiaUSA
  3. 3.Department of Otolaryngology-Head Neck SurgeryKaradeniz Technical University, School of MedicineTrabzonTurkey
  4. 4.Department of Otolaryngology-Head Neck SurgeryEskisehir Osmangazi University, School of MedicineEskişehirTurkey

Personalised recommendations